Bixiye
P27-16 Changes to Prior Authorization Requirements for Select Services for Commercial Products
Taariikhda wax ku ool ah ee barnaamijka: Jun 08, 2016
Natiijooyinka Raadinta
Soo bandhiga 3261 - 3270 ee natiijooyinka 3688
Bixiye
P4-17 Addition of Drug to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
Taariikhda uu dhaqangalayo Barnaamijka: Jan 30, 2017
Bixiye
P34-16 New Drug-Related Prior Authorization Criteria for Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blocker Prior Authorization with Quantity Limit Program
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2016
Bixiye
P47-16 New Drug-Related Prior Authorization Requirements for Botulinum Toxin, Remicade, Rituxan and Biologic Immunomodulators
Taariikhda uu dhaqangalayo barnaamijka: Okt 10, 2016
Bixiye
P50-16 Addition of a Drug (Xiidra) to the Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2016
Bixiye
P53-16 New Notification Requirement for Outpatient Dialysis Services for Commercial Products and Subscribers in Government Programs
Taariikhda uu dhaqangalayo Barnaamijka: Nov 09, 2016
Bixiye
P43R1-16 Updated: Third Party Payments of Premium and/or Cost-Sharing
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2016
Bixiye
P37-16 Addition of a Drug (Epclusa) to the Hepatitis C Second Generation Prior Authorization with Quantity Limit Program
Taariikhda barnaamijka Dhaqangalayso Agosto 03, 2016
Bixiye
P24-17 AOR No Longer Required for Submission of Organization Determinations for Platinum Blue Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: May 18, 2017
Bixiye
P11R1-17 Revised: Pre-Admission Notification Requirement for Admissions effective June 1, 2017
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2017